CYP3A4 and rhabdomyolysis: With regards to rosuvastatin, which is not metabolized by CYP3A4 and exhibits greater excretion by the kidneys, pantoprazole, omeprazole, and other proton-pump inhibitors competitively inhibit OAT3 activity and prolong elevated serum concentration, resulting in increased risk of statin-induced rhabdomyolysis [102,103,104].